For the quarter ended September 30, 2026, Globus posted $763.7 million in sales, down 0.7% from a year earlier.
Globus Medical Profits Climb as Sales Slip

Net income increased 18.7% to $141.2 million.
This is a wealth creation company – and, by ‘wealth creation’, we’re referring to more cash profits, versus Wall Street’s business model of finding a greater fool to buy stock.
The Quarter at a Glance
Dollars in millions. Quarterly results are for the three months ended September 30; cash balances are as of September 30.
| Financial Measure | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Sales | $763.7 | $769.0 | −0.7% |
| Gross profit | $509.2 | $493.9 | +3.1% |
| Operating profit | $177.6 | $137.4 | +29.3% |
| EBITDA | $245.8 | $213.7 | +15.0% |
| Free cash flow | $224.8 | $213.9 | +5.1% |
| Cash on hand | $441.3 | $371.8 | +18.7% |
Gross profit and operating profit are GAAP figures. EBITDA is before the company’s additional adjustments; EBITDA and free cash flow are non-GAAP measures. Cash on hand comprises cash and cash equivalents, excluding restricted cash and marketable securities.
The Good News: Core Sales Rose. The Bad News: Nevro Sales Collapsed
For the quarter, Globus’s base business sales, excluding Nevro, rose 3.0% to $690.0 million.
Nevro, however, lost 25.7% of its business coming in at $73.7 million from $99.3 million last year.
International sales were also a drag on sales growth, falling 5.7% to $142.7 million. U.S. sales edged up 0.5% to $621.0 million.
President and CEO Keith Pfeil said U.S. Spine grew 2% against double-digit growth in the comparable 2025 quarter. He pointed to average growth in the mid-single digits over two years as evidence that Globus continues to capture market share.
Robots Supply the Momentum
Enabling Technologies delivered the liveliest growth. Revenue increased 24.3% to $34.9 million, while Globus deployed 73% more robot and navigation units than a year earlier.
Pfeil described a strategy connecting and integrating patient selection, surgical techniques, complementary implants and technology across the procedure landscape as the flywheel driving sales growth and market penetration.
Margins Improve the Earnings Picture
Globus retained more profit from each sales dollar.
GAAP gross margin rose to 66.7% from 64.2%. Adjusted gross margin reached 69.5%, up 1.4 percentage points. CFO Kyle Kline said this marked the eighth consecutive quarter of sequential improvement in adjusted gross margin.
Operating profit increased 29.3% to $177.6 million, lifting operating margin to 23.2% from 17.9%. Selling, general and administrative expenses declined $25.1 million, while research and development spending fell $3.5 million.
Lower litigation provisions also helped the earnings comparison, falling to $3.7 million from $28.3 million. That contributes to the difference between the growth in reported and adjusted earnings. GAAP diluted earnings per share rose 18.2% to $1.04, while adjusted EPS increased to $1.23 from $1.18.
Adjusted EBITDA rose 3.8% to $262.2 million, with its margin improving to 34.3% from 32.8%. Globus’s adjusted measure excludes additional items such as stock compensation and litigation provisions.
Cash Gives the Buyback Room
Operating cash flow reached $265.2 million. After $40.4 million in capital expenditures, free cash flow totaled $224.8 million, up 5.1%.
Cash and cash equivalents stood at $441.3 million, compared with $371.8 million a year earlier. Including short- and long-term marketable securities, Globus held $871.2 million, excluding restricted cash.
On November 2, the board increased the existing share repurchase authorization by $500 million.
Globus had already repurchased $279.0 million of shares during the first nine months of 2026. The expanded authorization gives management more flexibility to return cash to shareholders while considering other investment opportunities.
What will Globus Buy Next?
Globus now expects sales will land at around $3.09 billion for 2026, down from its previous range of $3.18 billion to $3.22 billion. Adjusted EPS guidance remains $4.95 to $5.05, representing growth of 24.4% to 26.9%. Management is asking improved profitability to carry more of the year’s earnings story.
But, of course, the real story is Globus’s steadily rising cash war chest. Remember, cash increased 19% in a down sales Q3 quarter.
What’s GMED going to do with all that cash?
Buy more ortho companies – which are currently trading at historically low valuations and whose owners (looking at you SNN and JNJ) want to move on to next gen shiny objects – metabolic, biologic and pharmacologic products.
Frankly, David Paul can probably manage today’s recon business better than either Namal Nawana (Depuy Synthes) or Deepak Nath (Smith & Nephew).
Source: Globus Medical, Inc.
Author
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Globus Medical reported a slight sales decline of 0.7% to $763.7 million, yet net income surged 18.7% to $141.2 million for Q3 2026. Core business sales, excluding Nevro, grew 3.0%, while Nevro sales collapsed 25.7%. The company's strategy emphasizes profitability and leveraging a growing cash reserve for potential acquisitions, alongside significant share repurchases.
- U.S. Spine growth and Enabling Technologies (robotics/navigation) revenue increase of 24.3% indicate market share capture and strategic technology adoption.
- Increased cash on hand and expanded share repurchase authorization signal financial strength and potential for strategic M&A in the orthopedic market.
PhD Lens: Clinical and outcomes impact
Globus Medical's Q3 2026 results showed an 18.7% increase in net income despite a 0.7% sales dip. Enabling Technologies, including robotics and navigation units, demonstrated robust growth of 24.3%, with 73% more units deployed. Conversely, Nevro sales experienced a significant 25.7% decline, impacting overall revenue, while U.S. Spine grew 2%.
- Growth in Enabling Technologies highlights the increasing adoption and integration of advanced robotic and navigation systems in surgical procedures.
- The substantial decline in Nevro sales warrants further investigation into clinical efficacy, market acceptance, or competitive landscape factors.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.